Supplementary material for the financial results for
the year ending March 31, 2023
May 2023
(Stock code: 4553)
2023
Notes to and summary of the disclosure of financial results for 2023/03
Notes
- Sunsho Pharmaceutical, which became a subsidiary in March 2022, has been included in the consolidated balance sheets since 2022/03 and the consolidated statements of income since 2023/03.
- Due to the change in the fiscal year end of Towa HD and Sunsho Pharmaceutical, the consolidated fiscal year of both companies for the fiscal year ending March 31, 2023 is 15 months from January 1, 2022 to March 31, 2023.
- The actual figures for Towa HD and Sunsho Pharmaceutical for the fiscal year ending March 31, 2023, adjusted from 15 months to 12 months, are disclosed as a reference for comparison purposes.
- When comparing with the actual figures for the period ending March 31, 2022, the actual results for the period from January to December 2022 (" Adjusted Results (i)") are used.
- When comparing with the planned figures for the fiscal year ending March 31, 2024, the actual results for the period from April 2022 to March 2023 ("Adjusted Results (ii)") are used.
- On May 10, we announced a revision to our full-year consolidated earnings forecast for the fiscal year ending March 31, 2023
- On May 15, we announced a revision to our mid-term consolidated earnings forecast of the 5th Mid-term Business Plan 2021-2023「PROACTIVEⅡ」.
2023 | 1 |
Notes to and summary of the disclosure of financial results for 2023/03
Summary
●Both actual and adjusted results increased in sales and decreased in income from the previous fiscal year, mainly due to the inclusion of Sunsho Pharmaceutical in the scope of consolidation from the fiscal year ending March 31, 2023.
2023/03 Actual Results | 2023/03 Adjusted Results (i) | 2022/03 | |||
Fiscal period | (Overseas & Sunsho 15 months, | (Overseas & Sunsho 12 months, | |||
Actual Results | |||||
January 2022 - March 2023) | January 2022 - December 2022 ) | ||||
Item | (JPY billion) | YOY change (%) | (JPY billion) | YOY change (%) | (JPY billion) |
Net sales | 208.9 | + 26.2 | 192.0 | + 15.9 | 165.6 |
Operating | 5.5 | - 71.2 | 6.8 | - 64.7 | 19.2 |
profit | |||||
●Production volume (Non-consolidated; tablets and capsules only)
- Approx. 12.9 billion tablets, up approx. 14.2% year on year
●Sales volume (Non-consolidated; tablets and capsules only)
- Approx. 11.4 billion tablets, down approx. 2.0% year on year
●Increases in raw material costs and utilities expenses
- Raw materials: Increased by several percentage points year on year due to higher resource prices and a weaker yen
- Utilities expenses: Increased by approx. 65% year on year
2023 | 2 |
Contents
- Outline of financial results for 2023/03
- Outline of financial results for 2023/03 - Progress rate
- Balance sheets, capital expenditure and depreciation
- Full-yearplan for 2024/03
2023 | 3 |
Contents
1. Outline of financial results for 2023/03
Consolidated
Segment information
Domestic segment
Breakdown
Net sales by supplement year (Non-consolidated) Net sales by distribution channel (Non-consolidated)
Number of customers by customer segment (Non-consolidated) Selling, general and administrative expenses (Domestic segment)
Overseas segment
By region
Sales ratio of products released in the last three years
Approved and new products for 2023/03
- Outline of financial results for 2023/03 - Progress rate
- Balance sheets, capital expenditure and depreciation
- Full-yearplan for 2024/03
2023 | 4 |